Financials in USD. Standardized financial statements.
A compact view of how Altimmune, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $41,000 | $20,000 | $426,000 | -$68,000 | $4.41M | $8.19M | $5.80M | $10.33M | $41,503 | $5.23M |
| Revenue Growth? | +105.0% | -95.3% | +726.5% | -101.5% | -46.1% | +41.1% | -43.8% | +24792.6% | -99.2% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $0 | $33.51M | $0 | $18.46M | $18.41M | $7.22M |
| Gross Profit? | $41,000 | $20,000 | $426,000 | -$68,000 | $4.41M | -$25.32M | $5.80M | -$8.13M | -$18.36M | -$1.99M |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | -309.4% | +100.0% | -78.7% | -44249.4% | -38.1% |
| Operating Expenses? | $94.53M | $103.19M | $96.36M | $87.67M | $101.32M | $29.47M | $27.27M | $28.22M | $16.17M | $16.49M |
| Operating Income? | -$94.49M | -$103.17M | -$95.93M | -$87.74M | -$96.91M | -$54.80M | -$21.46M | -$42.83M | -$52.05M | -$11.26M |
| EBITDA? | -$87.03M | -$94.81M | -$87.94M | -$84.41M | -$96.53M | -$38.10M | -$20.19M | -$44.72M | -$51.76M | -$10.91M |
| Income Before Tax | -$88.77M | -$95.06M | -$88.45M | -$84.91M | -$97.09M | -$43.63M | -$20.58M | -$45.32M | -$52.06M | $205.02M |
| Income Tax Expense | -$681,000 | $0 | $0 | -$197,000 | $0 | $5.42M | -$58,500 | -$6.15M | -$5.64M | $11.17M |
| Net Income? | -$88.09M | -$95.06M | -$88.45M | -$84.71M | -$97.09M | -$49.04M | -$20.52M | -$39.17M | -$46.43M | $193.85M |
| EPS? | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 | $-1.91 | $-1.56 | $-13.98 | $-108.77 | $-49.80 |
| Diluted EPS? | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 | $-1.91 | $-1.56 | $-13.98 | $-108.77 | $-49.80 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality